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VaccinesVaccines based on adenovirus (Ad) vectors are currently in development against several pathogens.
However, neutralizing antibodies (NAb) to human adenovirus type 5 (AdHu5), the best-studied vector, are
highly prevalent in humans worldwide. Less-prevalent adenoviruses, including human and simian serotypes,
provide alternative vaccine platforms. In this study, sera from 200 Brazilian human subjects and New-World
monkeys were tested for NAb titers to human serotypes AdHu5 and AdHu26 and chimpanzee-origin Ad
viruses of serotype 6 (AdC6) and serotype 68 (AdC68). Seroprevalence rates of NAb in humans were 69.5%
for AdHu5, 44% for AdHu26, 21% for AdC6 and 23.5% for AdC68. In addition, NAb titers to human Ad were
consistently higher than those found to simian serotypes. Surprisingly, sera from some New-World monkey
species were able to neutralize AdC6 and/or AdC68. A possible explanation for these ﬁndings and the
implications for the development of Ad-vector vaccines are discussed in detail.ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Adenoviruses (Ad), belonging to the Adenoviridae family, are
nonenveloped DNA viruses that have been studied as vaccine vectors
as they are highly immunogenic, stable, safe and easy to manipulate
(Tatsis and Ertl, 2004). Recombinant Ad vectors elicit potent humoral
and cellular immunity, especially CD8+T cells, against their transgene
products. Ad vectors are currently considered as vaccine candidates
against several intracellular pathogens, including HIV (Buchbinder
et al., 2008), Plasmodium falciparum (Shott et al., 2008), Trypanosoma
cruzi (de Alencar et al., 2009) and Mycobacterium tuberculosis (Mu
et al., 2009).
Human adenovirus serotype 5 (AdHu5) is the best-studied
serotype. However, humans are commonly infected with AdHu5
early in life and consequently develop speciﬁc neutralizing antibodies
(NAb) in childhood (Appaiahgari et al., 2007; Thorner et al., 2006). By
neutralizing the vector, antibodies dampen the transgene product-
speciﬁc immune responses elicited by recombinant AdHu5-based
vaccines, as was shown in studies with mice (Barouch et al., 2004),rhesus monkeys (Casimiro et al., 2003) and humans (Catanzaro et al.,
2006). These ﬁndings may hamper clinical use of AdHu5 vectors as
vaccine carriers since seroprevalence of NAb to AdHu5 is very high
worldwide, particularly in the developing world (Dudareva et al.,
2009; Mast et al., 2010; Pilankatta et al., 2010), where vaccines to
pathogens such as HIV or Plasmodium are most direly needed.
To overcome this drawback, rare adenovirus serotypes can be
employed as substitutes for or in combination with AdHu5 in vaccine
strategies. Pre-clinical studies demonstrated that, among rare human
adenovirus serotypes, the human adenovirus type 26 (AdHu26) is one
of the most immunogenic vectors, even though it is not as
immunogenic as AdHu5 (Abbink et al., 2007). Moreover, AdHu26 is
currently been employed in two Phase-I clinical trials as an HIV-1
vaccine vector candidate (ClinicalTrials, 2010). Another source of rare
adenovirus serotypes includes those from other species, such as
chimpanzees. In particular, the chimpanzee adenovirus serotypes
AdC6 and AdC68 ﬁgure among promising candidates as vaccine
carriers (revised in Tatsis and Ertl, 2004). Both AdC viruses, which are
from two distinct serotypes related to the human adenovirus serotype
4, are able to grow in HEK293 complementing cells and are not cross-
neutralized by antibodies against common human adenovirus
serotypes (Farina et al., 2001). In addition, we have demonstrated in
pre-clinical studies that AdC6 and AdC68 vectors are highly
Fig. 1. Neutralizing antibody titers to human (AdHu5 and AdHu26) and chimpanzee
(AdC6 and AdC68) adenoviruses in humans, common marmosets (Callithrix jacchus)
and capuchin monkeys (Cebus libidinosus) from Brazil. Symbols: square = median,
rectangle = interquartile range, whisker = non-outlier range, and asterisk = outlier.
2 Rapid Communicationimmunogenic and effective at inducing cytotoxic T lymphocytes
speciﬁc to HIV-1 antigens (Pinto et al., 2004; Reyes-Sandoval et al.,
2004, Souza et al., 2007).
Nonetheless, studies comparing the occurrence of NAb to AdHu5,
AdHu26, AdC6 and AdC68 are limited and mainly available for North
America, Europe and Africa (Mast et al., 2010; Xiang et al., 2006).
These reports suggest considerable differences in NAb prevalence
according to geographic region. Prevalence rates in Latin America are
poorly known, with only one study reporting NAb to human
adenoviruses in Brazil (Mast et al., 2010). Because these populations
may become recipients of Ad-based vaccines, it is pivotal to assess
pre-immunity to Ad-vector candidates. Therefore, the aim of the
present study was to determine NAb titers to AdHu5, as well as to its
possible substitutes AdHu26, AdC6 and AdC68 in Brazil. In order to
better understand the origin of NAbs to AdC viruses found in humans,
samples from non-human primates were also evaluated.
Results
Neutralizing antibodies to adenoviral vectors in humans
NAb titers to AdHu5, AdHu26, AdC6 and AdC68 were assessed by a
virus neutralization assaywith GFP-expressing recombinant Ad vectors.
Antibodies against AdHu5 and AdHu26were found in 69.5% and 44% of
human samples, respectively (Table 1). Unexpectedly, 21% and 23.5% of
Brazilian subjects also featured NAb to chimpanzee AdC6 and AdC68
serotypes, respectively. The seroprevalence rate to AdHu5 was
statistically higher than to AdHu26 (P=0.0067, χ2 test), AdC6, and
AdC68 (Pb0.0001 in both cases, χ2 test). Therefore, among our Brazilian
study population, pre-existing immunity is more common to AdHu5
than to AdHu26, AdC6 and AdC68. In accordance to the seroprevalence
ﬁndings, Brazilians also featured higher NAb titers to AdHu5 than to
AdHu26, AdC6 or AdC68 (Pb0.0001, Friedman ANOVA test). As shown
in Fig. 1, NAb titers to AdHu5 were found at a wider range and the
median titer (320) was higher than those to the other vectors (20 for
AdHu26 and 10 for AdC6 and AdC68). Accordingly, 53% of the Brazilian
subjects had high (N200) NAb titers to AdHu5, and 22% exhibited titers
above 1000, whereas only 9% of Brazilians had NAb titers N200 to
AdHu26 (Fig. 2). Titers were lower to AdC6 and AdC68, only 2.5% and
2.0% of human samples showed NAb titers N200 to these viruses,
respectively (Fig. 2). Interestingly, NAb titers N1000 were not found to
AdHu26, AdC6 or AdC68. Taken together, these ﬁndings indicate that
antibody responses against AdHu5 are stronger or more sustained than
those to the other viruses, suggesting that the use of Ad vectors other
than AdHu5 may be considered as vaccine carriers in Brazil.
Neutralizing antibodies to adenoviral vectors in New-World monkeys
The unexpected occurrence of NAb to simian Ad among Brazilian
adults at rates higher than previously reported in the US or Thailand
gave rise to the hypothesis that chimpanzee adenoviruses may
circulate among monkeys from Brazil, notwithstanding that chim-
panzees are Old-World primates and are typically only found in zoos
in Brazil. Therefore, samples from two monkey species that areTable 1
Seroprevalence of neutralizing antibodies to human (AdHu5 and AdHu26) and simian
(AdC6 and AdC68) adenoviruses in Brazil.
Species n Positive samplesa (%)
AdHu5 AdHu26 AdC6 AdC68
Human (Homo sapiens) 200 69.5 44.0 21.0 23.5
Common marmoset (Callithrix jacchus) 16 31.3 0.0 93.8 100.0
Capuchin monkey (Cebus libidinosus) 18 5.5 0.0 5.5 5.5
a Samples with NAb titers higher than 20 were scored as positive.commonly in contact with Brazilians, common marmosets (Callithrix
jacchus) and capuchin monkeys (Cebus libidinosus), were also
analysed for NAb. Both monkey species were either free-ranging or
kept as pets. Neutralizing antibodies to AdHu5, AdC6 and AdC68, but
not to AdHu26, were found in sera from common marmosets, as
shown in Table 1. In this species, NAb to AdC6 and AdC68 were more
frequent than to AdHu5 (Pb0.02 in both cases, χ2 test). Additionally,
NAb titers to AdC6 and AdC68 were higher than those observed to
AdHu5 (Pb0.0001, Friedman ANOVA test) (Fig. 1). Nonetheless, NAb
titers N200 among common marmosets were rare and found only for
AdC6 (Fig. 2). In contrast, sera from capuchin monkeys were not able
to neutralize AdHu5, AdHu26, AdC6 or AdC68 (Table 1), except for one
specimen which featured NAb titers 640 to AdHu5 and AdC68, and
320 to AdC6 (Fig. 1). We had previously tested sera from chimpanzees
obtained from zoos of the United States for antibodies to the AdC
viruses and found such antibodies in all of the animals (Xiang et al.,
2006). To assess if antibodies to AdC viruses were common in New-
World monkeys, we tested sera obtained from an additional 84
animals belonging to a variety of species and living in primate centers
and zoos in the United States for NAbs to AdHu5, AdHu26 and AdC6.
None of the animals were positive for AdHu5 or AdHu26 virus
Fig. 2. Distribution of serum samples from humans, common marmosets (Callithrix jacchus) and capuchin monkeys (Cebus libidinosus) from Brazil according to the NAb titer to
human (AdHu5 and AdHu26) and chimpanzee (AdC6 and AdC68) adenoviruses.
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for AdC6 at a titer of 20, three additional tamarins (1 S. oedipus and 2
Saguinus mystax) scored at a 10 titer for NAbs to AdC6. In addition we
tested sera from 39 rhesus macaques obtained from a primate facility,
which also houses chimpanzees, for antibodies to AdC6 to assess if the
AdC viruses readily spread between different primate species. As can
be seen in Table 2, 12.5% of rhesus macaques had antibodies to AdC6;
4 had low titers of 20 and only one animal had titer of 80.Table 2
Neutralizing antibody titers to AdC6 among New and Old-World monkeys from the
United States.
Species n NAb titer to AdC6a (%)
Undetectable 10 20 40 80
Capuchinb (Cebus apella) 23 100 0 0 0 0
Capuchinb (Cebus albifrons) 1 100 0 0 0 0
Marmosetb (Callithrix jacchus) 5 100 0 0 0 0
Geoffrey's
marmosetb
(Callithrix geoffroyi) 5 100 0 0 0 0
Owl monkeyb (Aotus trivirgatus) 4 100 0 0 0 0
White-faced Saki
monkeyb
(Pithecia pithecia) 7 100 0 0 0 0
Black-handed
spider monkeyb
(Ateles geoffroyi) 8 100 0 0 0 0
Brown-handed
spider monkeyb
(Ateles fusciceps) 3 100 0 0 0 0
Squirrel monkeyb (Samiri bolivinis) 4 100 0 0 0 0
Squirrel monkeyb (Saimiri boloviensis
peruviensia)
3 100 0 0 0 0
Tamarinb (Sagiunus mystax) 12 83 17 0 0 0
Tamarinb (Sagiunus oedipus) 9 78 11 11 0 0
Rhesus macaquec (Macaca mullata) 39 87.5 0 10 0 2.5
a NAb titers to AdHu5 and AdHu26 were undetectable in all animals tested.
b New-World monkey.
c Old-World monkey.Discussion
Prior studies have reported a 60% NAb prevalence to AdHu5 in
Europe (Kostense et al., 2004; Mast et al., 2010), 35–70% in North
America (Nwanegbo et al., 2004; Sumida et al., 2005) 75–100% in
Asia (Pilankatta et al., 2010; Xiang et al., 2006) and 60–100% in
Africa (Abbink et al., 2007; Dudareva et al., 2009; Xiang et al.,
2006). Here we report 70% AdHu5 NAb prevalence among
Brazilians, thus reinforcing that these antibodies are frequent in
humans throughout the world. These ﬁndings are consistent with a
recent study indicating 80% NAb seroprevalence to AdHu5 in Brazil
(Mast et al., 2010). Neutralizing antibodies to AdHu5 are com-
monly present in human sera at high titers, especially in
developing countries. In Subsaharan Africa, 48% of human samples
featured NAb to AdHu5 at titers N1000 (Abbink et al., 2007). In the
present study, 22% of Brazilian subjects harbored NAb titers N1000
to AdHu5. Because high-titer NAb to Ad reduce the effectiveness of
vaccines based on the homologous Ad serotype (Casimiro et al.,
2003), these data discourage the clinical use of AdHu5-based
vectors as vaccine carriers.
Differently, AdHu26 seems to be less prevalent than AdHu5,
reaching NAb prevalence rates of 12% in North America, 60% in Asia,
20–90% in Africa (Abbink et al., 2007; Mast et al., 2010; Thorner et al.,
2006) and, as shown here, 44% in Brazil. Notably, NAb titers to
AdHu26 are considerably lower than to AdHu5. In this study, while
53% of human samples featured NAb titers to AdHu5 N200, 9%
harbored NAb to AdHu26 at these titers. AdHu26 has been shown to
bemore immunogenic than other rare human Ad serotypes andmight
be useful as a surrogate vaccine candidate for AdHu5 in countries with
low seroprevalence rates (Abbink et al., 2007). Notwithstanding, it
remains to be investigated at what titers NAb affect transgene
product-speciﬁc immune responses to AdHu26 vectors, which are
not as immunogenic as AdHu5 vectors.
4 Rapid CommunicationAs demonstrated in the present report, NAb titers to AdC viruses
were signiﬁcantly lower than to human Ad, and less than 3% of
Brazilian subjects featured NAb at titers N200 to AdC. Considering the
problem of NAb pre-existence, in addition to the pre-clinical studies
that provide evidence of the high immunogenicity of AdC6 and AdC68,
our ﬁndings indicate that chimpanzee adenoviruses may be better
vaccine vector candidates than human Ad.
The AdC viruses evaluated in this study are described as
chimpanzee-speciﬁc viruses (Tatsis and Ertl, 2004), reaching sero-
prevalence rates of 90% in the species Pan troglodytes (Farina et al.,
2001; Xiang et al., 2006). This is the ﬁrst report to describe NAb to AdC
viruses in Latin America, reporting seroprevalence rates of approxi-
mately 20% in humans in Brazil for either AdC6 or AdC68. Neutralizing
antibodies against AdC have been reported to occur in lower
prevalence rates in North America (2–4%), and even in chimpanzee-
endemic regions, such as Southeast Asia (1.5–3%) and Africa (2–20%)
(Xiang et al., 2006). The causative aspects for these ﬁndings among
our Brazilian study population are difﬁcult to be addressed, especially
because chimpanzees are not endemic in the Americas. It is
reasonable to suppose that AdC viruses might be cross-neutralized
by antibodies against human Ad viruses. However, both AdC6 and
AdC68 belong to subgenera E of Adenoviridae and AdHu4, the only
human serotype of this group, does not show serological cross-
reactivity with AdC68 (Xiang et al., 2002). Nonetheless, it is also
possible that human antibodies speciﬁc to other pathogens endemic
in Brazil could cross-react with AdC viruses.
Alternatively, Ad viruses serologically related to AdC viruses may
circulate in other primate species, including New-World monkeys,
and the relatively high seroprevalence rates of NAb to AdC viruses in
Brazilians might be caused by spillover infections from monkeys to
humans. The latter possibility is further supported by our ﬁnding that
some of the New-World monkeys residing in Brazil had antibodies
that neutralized AdC viruses while such antibodies were not detected
in New-World monkeys residing in the USA. In fact, NAb to AdC6 and
AdC68 were found in sera from 93.8 and 100% of commonmarmosets
from Brazil, respectively, which clearly corroborates this hypothesis.
Adenoviruses have co-evolved with their hosts for more than
400 million years (Benkö and Harrach, 2003). Therefore, due to
their phylogenetic proximity, it is possible that humans and monkeys
have already been infected with similar adenoviruses. Human Ad
viruses have been isolated from Old-World monkeys in China, and
zoonotic transmissions to humans have also been suggested (Roy
et al., 2009). Furthermore, as shown here, NAb to AdC viruses could be
detected at low levels in some sera from rhesus macaques living in
captivity at a facility where they were likely to have contact with
chimpanzee feces, which commonly contain infectious Ad viruses
(Roy et al., 2009).
We also observed absence of NAb to Ad in capuchin monkeys from
Brazil. These ﬁndings are in agreement with an extensive study of sera
from a variety of New-World monkeys kept at primate centers and
zoos in the United States, which failed to show antibodies to AdHu5
and AdHu26 virus. Additionally, none of the marmosets from the USA
had antibodies to AdC6 virus and only one tamarin, which as
marmosets belong to the Callitrichinae family, had only low NAb
titers to AdC6. Therefore, the occurrence of NAb to AdC6, AdC68 and
AdHu5 among common marmosets from Brazil is puzzling.
Differences in prevalence of NAb to Ad in sera from common
marmosets from Brazil or USA facilities are curious andmay reﬂect the
more controlled environment of the latter. It is also valuable of note
that the common marmosets from Brazil included in this study were
from a restricted population from a remnant vegetation area within
the city of Salvador (BA). Since these free-ranging animals were
located within an urban region, they might have been in contact with
humans and may have contracted AdHu5 virus from them. In
addition, there is a zoo that harbors chimpanzees in Salvador.
Therefore, a possible explanation to our results is that the commonmarmosets were somehow in contact with chimpanzees, or chim-
panzee feces, andwere infected by AdC serotypes. A second possibility
is that the common marmosets from Brazil harbor pathogens such as
simian adenoviruses that induce antibodies capable of cross-neutral-
ization of AdC viruses. The speciﬁcity of such antibodies, however,
remains elusive and future studies are necessary to clarify this
important issue.
In conclusion, the present report shows that NAb to AdHu5 and
AdHu26 are commonly found in humans from Brazil, and seropreva-
lence rates of NAb to AdC6 and AdC68 are comparatively rare.
Unexpectedly, a few individuals, as well as common marmosets
residing in Brazil have NAb titers to AdC6 and AdC68, which may
indicate that these serotypes circulate in New-World monkeys in
Brazil and may thus not be chimpanzee viruses.
Materials and methods
Cells
HEK293 cells (American Type Culture Collection CRL-1573), a
human embryonic kidney cell line that expresses E-1 gene from
AdHu5, were cultured in Dulbecco's Modiﬁed Eagle's Medium
(DMEM; Cultilab) supplemented with 10% heat-inactivated fetal calf
serum (FCS; LGC), 100 UI/mL penicillin, 100 μg/mL streptomycin and
0.25 μg/mL amphotericin B (all from Sigma-Aldrich). Cells were
cultured to conﬂuency at 37 °C and 5% CO2, washed with PBS,
trypsinized, suspended in DMEM supplemented with 10% FCS, and
manually counted after trypan blue staining.
Recombinant adenoviruses
Replication-defective, GFP-expressing Ad vectors from serotypes
AdHu5, AdHu26, AdC6 and AdC68 were constructed in the Wistar
Institute's Vector Core Facility (Philadelphia, PA) based on a
previously described protocol (Davis et al., 2001). The recombinant
vectors were serially passaged on complementing HEK293 cells to
generate high-titer viral stocks. Adenovirus vectors were puriﬁed by
cesium chloride gradient centrifugation, dialyzed, diluted in PBS to a
ﬁnal concentration of 5×1012 viral particles/mL, and stored at−80 °C.
Human serum samples
Human serum samples were obtained from 200 healthy Brazilian
blood donors aged between 18 and 65. One hundred subjects were
recruited at Centro de Hematologia e Hemoterapia do Acre/
HEMOACRE (Rio Branco, AC), and one hundred subjects were
recruited at Hospital Universitário Polydoro Ernani de São Thiago
(Florianópolis, SC). At each site of enrollment, 50 male and 50 female
subjects were recruited. From each subject, 5 mL of peripheral blood
was collected in plastic tubes with clot activator and gel for serum
separation. Tubes were centrifuged at 1000 ×g for 15 min, and serum
samples were stored at−20 °C. Before use, sera were heat-inactivated
at 56 °C for 30 min. Ethical approval was obtained from the Ethics
Committee of Universidade Federal de Santa Catarina, and partici-
pants provided informed consent.
Non-human primate serum samples
Samples from captive and wild monkeys from Northeast Brazil
were included in the study. Sera from 16 common marmosets (C.
jacchus) and 18 capuchin monkeys (C. libidinosus) were provided by
Centro Nacional de Pesquisa e Conservação de Primatas Brasileiros
(João Pessoa, PB). In addition, 84 samples from other species of
Atelidae, Pithecelidae and Cebidae monkeys and 39 samples from
rhesus macaques were obtained from primate centers and zoos in the
United States. Samples were aliquoted and stored at −20 °C.
5Rapid CommunicationAdenovirus neutralization assays
Ad neutralization assays were performed as described previously
(Sprangers et al., 2003), with some modiﬁcations. The ratio of viral
particles per cell and the post-infection incubation period were
calibrated to optimize assay sensitivity. Brieﬂy, 1×107 viral particles
of GFP-expressing AdHu5, AdHu26, AdC6 or AdC68 were mixed with
twofold serial dilutions (ranging from 1:10 to 1:10,240) of heat-
inactivated sera and incubated for 1 h at 37 °C and 5% CO2 in 96-well
plates. After incubation, 2×104 HEK 293 cells were added per well.
Sera from BALB/c mice primed and boosted with 1×1010 viral
particles of GFP-expressing vectors were used as positive controls. As
negative control, DMEM was added instead of serum samples.
Following a 24 h incubation at 37 °C and 5% CO2, cells were ﬁxed
with paraformaldehyde 4% and nuclei staining was performed with
Hoechst 5 μg/mL. Plates were analysed under an epiﬂuorescence
microscope (BX41, Olympus) in 40× objective lense and ﬁelds were
photographed. NAb titers corresponded to the reciprocal dilutions in
which the ratio of GFP-expressing/Hoechst-stained cells reached
approximately 50% of the ratio observed in negative controls. Titers
higher than 20 were scored as positive for the presence of serotype-
speciﬁc NAb. For each Ad serotype, results are representative of two or
more independent experiments.
Data analysis
Statistical analyses were performed with Satistica 7 software.
Comparisons between seroprevalence rates of AdHu5 and the other
serotypes were made using chi-square (χ2) test. In order to compare
neutralizing antibody titers among the four adenoviral serotypes,
Friedman ANOVA test was applied. In all tests, P valuesb0.05 were
assumed as signiﬁcant.
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